<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication" xmlns:n2016="http://publications.europa.eu/resource/schema/ted/2016/nuts" xsi:schemaLocation="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication TED_EXPORT.xsd" VERSION="R2.0.9.S03.E01" DOC_ID="470495-2020" EDITION="2020194"><TECHNICAL_SECTION><RECEPTION_ID>20-485144-001</RECEPTION_ID><DELETION_DATE>20201105</DELETION_DATE><FORM_LG_LIST>EN </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="http://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>194</NO_OJ><DATE_PUB>20201006</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2020/S 194-470495</NO_DOC_OJS><URI_LIST><URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:470495-2020:TEXT:EN:HTML</URI_DOC></URI_LIST><LG_ORIG>EN</LG_ORIG><ISO_COUNTRY VALUE="UK"/><IA_URL_GENERAL>https://www.england.nhs.uk/</IA_URL_GENERAL><IA_URL_ETENDERING>http://health.atamis.co.uk</IA_URL_ETENDERING><ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV><n2016:PERFORMANCE_NUTS CODE="UK">UNITED KINGDOM</n2016:PERFORMANCE_NUTS><n2016:CA_CE_NUTS CODE="UK">UNITED KINGDOM</n2016:CA_CE_NUTS><VALUES><VALUE TYPE="ESTIMATED_TOTAL" CURRENCY="GBP">754830788.00</VALUE></VALUES></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20201001</DS_DATE_DISPATCH><DT_DATE_FOR_SUBMISSION>20201105 13:00</DT_DATE_FOR_SUBMISSION><AA_AUTHORITY_TYPE CODE="1">Ministry or any other national or federal authority</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="3">Contract notice</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="1">Open procedure</PR_PROC><RP_REGULATION CODE="Z">Not specified</RP_REGULATION><TY_TYPE_BID CODE="1">Submission for all lots</TY_TYPE_BID><AC_AWARD_CRIT CODE="2">The most economic tender</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES><HEADING>08B02</HEADING><INITIATOR>08</INITIATOR></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="BG"><TI_CY>Обединено кралство</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Фармацевтични продукти</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Spojené království/Velká Británie</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Léčivé přípravky a zdravotnické prostředky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DA"><TI_CY>Forenede Kongerige, Det</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Lægemidler</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>das Vereinigte Königreich</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Arzneimittel</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Ηνωμένο Βασίλειο</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Φαρμακευτικά προϊόντα</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>United Kingdom</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Productos farmacéuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Suurbritannia / Ühendkuningriik</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Ravimid</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Yhdistynyt kuningaskunta</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaseuttiset tuotteet</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Royaume-Uni</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produits pharmaceutiques</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Ríocht Aontaithe, an</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Ujedinjena Kraljevina</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Egyesült Királyság</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Gyógyszerészeti termékek</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Regno Unito</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Prodotti farmaceutici</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmacijos produktai</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Apvienotā Karaliste</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmācijas izstrādājumi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>Ir-Renju Unit</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Prodotti farmaċewtiċi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Verenigd Koninkrijk</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutische producten</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Zjednoczone Królestwo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produkty farmaceutyczne</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produtos farmacêuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Regatul Unit</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produse farmaceutice</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Spojené kráľovstvo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutické výrobky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Združeno kraljestvo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmacevtski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Förenade kungariket</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Läkemedel</P></TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="EN">The NHS Commissioning Board (operating under the name of NHS England)</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><F02_2014 CATEGORY="ORIGINAL" FORM="F02" LG="EN"><LEGAL_BASIS VALUE="32014L0024"/><CONTRACTING_BODY><ADDRESS_CONTRACTING_BODY><OFFICIALNAME>The NHS Commissioning Board (operating under the name of NHS England)</OFFICIALNAME><ADDRESS>2nd Floor, Rutland House</ADDRESS><TOWN>Runcorn</TOWN><POSTAL_CODE>WA7 2ES</POSTAL_CODE><COUNTRY VALUE="UK"/><CONTACT_POINT>Katie Noonan</CONTACT_POINT><E_MAIL>katie.noonan@nhs.net</E_MAIL><n2016:NUTS CODE="UK"/><URL_GENERAL>https://www.england.nhs.uk/</URL_GENERAL><URL_BUYER>https://www.england.nhs.uk/</URL_BUYER></ADDRESS_CONTRACTING_BODY><CENTRAL_PURCHASING/><DOCUMENT_FULL/><URL_DOCUMENT>http://health.atamis.co.uk</URL_DOCUMENT><ADDRESS_FURTHER_INFO_IDEM/><URL_PARTICIPATION>http://health.atamis.co.uk</URL_PARTICIPATION><ADDRESS_PARTICIPATION_IDEM/><URL_TOOL>http://health.atamis.co.uk</URL_TOOL><CA_TYPE VALUE="MINISTRY"/><CA_ACTIVITY VALUE="HEALTH"/></CONTRACTING_BODY><OBJECT_CONTRACT><TITLE><P>NHS Framework for the Midlands and East, Branded Medicines — Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.</P></TITLE><REFERENCE_NUMBER>CM/PHR/20/5591</REFERENCE_NUMBER><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN><TYPE_CONTRACT CTYPE="SUPPLIES"/><SHORT_DESCR><P>CM/PHR/20/5591/01 — Midlands and East, Branded Medicines — Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.</P><P>CM/PHR/20/5591/02 — Midlands and East Branded Medicines — Annual Tranche, cytokine modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for migraine and asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.</P><P>CM/PHR/20/5591/03 — Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021.</P><P>CM/PHR/20/5591/04 — Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021.</P></SHORT_DESCR><VAL_ESTIMATED_TOTAL CURRENCY="GBP">754830788.00</VAL_ESTIMATED_TOTAL><LOT_DIVISION><LOT_ALL/></LOT_DIVISION><OBJECT_DESCR ITEM="1"><TITLE><P>Lot 4: (SOFE) — Interleukin Inhibitors, JAK Inhibitors, Migraine and Asthma</P></TITLE><LOT_NO>4</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UK"/><MAIN_SITE><P>Please refer to document No 10 for a full list of participating authorities.</P></MAIN_SITE><SHORT_DESCR><P>CM/PHR/20/5591/04 — NHS Framework agreement for the supply of interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021.</P></SHORT_DESCR><AC><AC_PROCUREMENT_DOC/></AC><DATE_START>2021-03-01</DATE_START><DATE_END>2021-08-31</DATE_END><NO_RENEWAL/><ACCEPTED_VARIANTS/><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR><OBJECT_DESCR ITEM="2"><TITLE><P>Lot 3: (LNW) — Interleukin Inhibitors, JAK Inhibitors, Migraine and Asthma</P></TITLE><LOT_NO>3</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UK"/><MAIN_SITE><P>Please refer to document No 10 for a full list of participating authorities.</P></MAIN_SITE><SHORT_DESCR><P>CM/PHR/20/5591/03 — NHS Framework agreement for the supply of interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021.</P></SHORT_DESCR><AC><AC_PROCUREMENT_DOC/></AC><DATE_START>2021-03-01</DATE_START><DATE_END>2021-08-31</DATE_END><NO_RENEWAL/><ACCEPTED_VARIANTS/><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR><OBJECT_DESCR ITEM="3"><TITLE><P>Lot 2: Midlands and East Cytokine Modulators and Other Monoclonal Antibodies</P></TITLE><LOT_NO>2</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UK"/><MAIN_SITE><P>Please refer to document No 10 for a full list of participating authorities.</P></MAIN_SITE><SHORT_DESCR><P>CM/PHR/20/5591/02 — NHS Framework for the Midlands and East Branded Medicines — annual tranche, cytokine modulators, other monoclonal antibodies interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.</P></SHORT_DESCR><AC><AC_PROCUREMENT_DOC/></AC><DATE_START>2021-03-01</DATE_START><DATE_END>2022-02-28</DATE_END><NO_RENEWAL/><ACCEPTED_VARIANTS/><OPTIONS/><OPTIONS_DESCR><P>There will be an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.</P></OPTIONS_DESCR><NO_EU_PROGR_RELATED/></OBJECT_DESCR><OBJECT_DESCR ITEM="4"><TITLE><P>Lot 1: Midlands and East (MAE) Tranche B</P></TITLE><LOT_NO>1</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UK"/><MAIN_SITE><P>Please refer to document No 10 for a full list of participating authorities.</P></MAIN_SITE><SHORT_DESCR><P>CM/PHR/20/5591/01 — NHS Framework for the Midlands and East, Branded Medicines — Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.</P></SHORT_DESCR><AC><AC_PROCUREMENT_DOC/></AC><DATE_START>2021-03-01</DATE_START><DATE_END>2022-02-28</DATE_END><NO_RENEWAL/><ACCEPTED_VARIANTS/><OPTIONS/><OPTIONS_DESCR><P>There will be an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.</P></OPTIONS_DESCR><NO_EU_PROGR_RELATED/></OBJECT_DESCR></OBJECT_CONTRACT><LEFTI><ECONOMIC_CRITERIA_DOC/></LEFTI><PROCEDURE><PT_OPEN/><FRAMEWORK><SEVERAL_OPERATORS/></FRAMEWORK><CONTRACT_COVERED_GPA/><DATE_RECEIPT_TENDERS>2020-11-05</DATE_RECEIPT_TENDERS><TIME_RECEIPT_TENDERS>13:00</TIME_RECEIPT_TENDERS><LANGUAGES><LANGUAGE VALUE="EN"/></LANGUAGES><DATE_TENDER_VALID>2021-02-03</DATE_TENDER_VALID><OPENING_CONDITION><DATE_OPENING_TENDERS>2020-11-05</DATE_OPENING_TENDERS><TIME_OPENING_TENDERS>13:00</TIME_OPENING_TENDERS><PLACE><P>Runcorn.</P></PLACE><INFO_ADD><P>Commercial Medicines Unit employee.</P></INFO_ADD></OPENING_CONDITION></PROCEDURE><COMPLEMENTARY_INFO><NO_RECURRENT_PROCUREMENT/><EORDERING/><EINVOICING/><EPAYMENT/><INFO_ADD><P>Responding to this notice</P><P>Any supplier may be disqualified who does not respond to the following in the requisite manner.</P><P>1) Submission of expression of interest and procurement specific information</P><P>This procurement exercise will be conducted on the eTendering portal at https://health-family.force.com/s/Welcome Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:</P><P>1.1) if not already registered, candidates should register on the eTendering portal at https://health-family.force.com/s/Welcome and click the link to register:</P><P>— agree to the user agreement,</P><P>— populate company details;</P><P>1.2) once registered, candidates must register interest as follows:</P><P>— log to the portal,</P><P>— select ‘Find Opportunities’ from the supplier home screen, use the ‘Sort by’: facility to find this opportunity and select the bold blue title to select,</P><P>— review opportunity details and click ‘Register Interest’,</P><P>— as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity);</P><P>1.3) there is a supplier user guide on using the system and candidates can contact the Atamis helpdesk at support-health@atamis.co.uk or by calling 08009956035 for technical assistance when completing responses.</P><P>2) General supplier information.</P><P>To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows.</P><P>2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk and select ‘Register’ at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&amp;B. Candidates must obtain a Dun and Bradstreet (D&amp;B) D-U-N-S® Number to enable registration on the system.</P><P>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&amp;B data will be supplied automatically by D&amp;B.</P><P>2.3) For further help or information concerning this telephone +44(0) 1614137982 or via the message function on the website.</P><P>Other contracting authorities</P><P>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.</P></INFO_ADD><ADDRESS_REVIEW_BODY><OFFICIALNAME>The High Court</OFFICIALNAME><ADDRESS>Strand</ADDRESS><TOWN>London</TOWN><POSTAL_CODE>WC2A 2LL</POSTAL_CODE><COUNTRY VALUE="UK"/><URL>https://www.gov.uk/courts-tribunals</URL></ADDRESS_REVIEW_BODY><DATE_DISPATCH_NOTICE>2020-10-01</DATE_DISPATCH_NOTICE></COMPLEMENTARY_INFO></F02_2014></FORM_SECTION></TED_EXPORT>